date of transplant, conditioning regimen, engraftment data (neutrophils and platelets), response, and survival data were derived from review of medical records. Determination of candidacy for ASCT and conditioning regimen were at the discretion of the treating physician.Baseline Charlson comorbidity risk index (CCI) and hematopoietic stem cell transplant comorbidity index (HCT-CI) were calculated for all patients. Comorbidity data were collected from review of medical records, and comorbidities were scored as previously published [6,7]. For both indices, a score of 0 was defined as low risk, a score of 1-2 was defined as intermediate risk, and a score of 3 or higher was considered high risk. Comorbidity risk scores were correlated with NRM, OS, and PFS.Primary endpoints for the analysis were progression-free survival (PFS) and overall survival (OS). OS was defined as the time from transplant until death or last follow up, and PFS was defined as the time from transplant until disease progression, death or last follow up. Treatment-related mortality (TRM) was defined as death within 100 days of transplant not attributed to progression of lymphoma. Analyses of OS and PFS were performed using the Kaplan-Meier method [12]. Confidence intervals were computed using a 95% T * 2 magnetic resonance imaging (MRI) provides rapid quantification of liver iron content (LIC). The reciprocal of T * 2 is directly proportional to iron and has been calibrated against LIC. There has, however, been few independent validation of the T * 2 method in a clinical setting. In 100 MRI studies on 75 pediatric patients being investigated for liver iron overload, we assess the accuracy and reproducibility of T * 2 -measured LIC, using regulatory approved T 2 -based FerriScan 1 for reference measurements. Results from independent analyses by two observers demonstrated robust inter-and intra-observer agreement (intraclass correlation coefficient (ICC) 5 0.99 and 1.0, respectively). T * 2 -measured and reference LIC were strongly correlated (r 5 0.94, P < 0.0001), with a regression slope of 0.97 over the range 0-25 mg Fe/g. The T * 2 technique is shown to be accurate and reproducible for rapid, non-invasive LIC quantification.Iron is used in the production of hemoglobin and is usually stored in the liver and spleen. In several pathologies, iron accumulates as a result of frequent blood transfusions to treat anemia (e.g., thalassemia, sickle cell disease) or as a result of excess iron absorption (e.g., hereditary hemochromatosis). Without treatment, excess iron can result in damage to various body organs, particularly endocrine, liver, and heart. The goal of treatment is to prevent liver damage and heart failure. Monitoring body iron content is, therefore, critical in managing patients with iron overload. Assessment of iron levels is conventionally performed with a liver biopsy, as this is the organ where iron first accumulates. The measured LIC is thus used as a surrogate for total body iron stores. However, biopsy is invasive and limited by samp...